HER2-positive DTCs/CTCs in breast cancer

Andreas D. Hartkopf; Malgorzata Banys; Tanja Fehm

doi:10.1007/978-3-642-28160-0_19

HER2-positive DTCs/CTCs in breast cancer

Andreas D. Hartkopf, Malgorzata Banys, Tanja Fehm

Clinic of Gynecology and Obstetrics

University of Tubingen

19 Citations (Scopus)

Abstract

The presence of circulating tumor cells (CTCs) in the blood as well as disseminated tumor cells (DTCs) in the bone marrow of breast cancer patients is associated with a worsened prognosis in the primary as well as in the metastatic situation. Next to their detection, evaluation of human epidermal growth factor receptor (HER2) expression is a valuable feature of CTCs/DTCs. As the HER2 status may change during disease progression CTCs/DTCs might (1) characterize the phenotype of minimal residual disease in the adjuvant setting and (2) serve as a "real time biopsy" of metastatic breast cancer. Phenotyping of CTCs/DTCs will thus help to understand mechanism of resistance to HER2-directed therapy. Moreover, patients that are likely to benefit from HER2-directed therapy despite a HER2-negative primary tumor might be identified.

Original language	English
Title of host publication	Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer
Editors	Michail Ignatiadis, Christos Sotiriou, Klaus Pantel
Number of pages	13
Publication date	2012
Pages	203-215
ISBN (Print)	9783642281594
DOIs	https://doi.org/10.1007/978-3-642-28160-0_19
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-642-28160-0_19

Cite this

@inbook{96389205df374cbb9d96a889f9d393d1,

title = "HER2-positive DTCs/CTCs in breast cancer",

abstract = "The presence of circulating tumor cells (CTCs) in the blood as well as disseminated tumor cells (DTCs) in the bone marrow of breast cancer patients is associated with a worsened prognosis in the primary as well as in the metastatic situation. Next to their detection, evaluation of human epidermal growth factor receptor (HER2) expression is a valuable feature of CTCs/DTCs. As the HER2 status may change during disease progression CTCs/DTCs might (1) characterize the phenotype of minimal residual disease in the adjuvant setting and (2) serve as a {"}real time biopsy{"} of metastatic breast cancer. Phenotyping of CTCs/DTCs will thus help to understand mechanism of resistance to HER2-directed therapy. Moreover, patients that are likely to benefit from HER2-directed therapy despite a HER2-negative primary tumor might be identified.",

author = "Hartkopf, \{Andreas D.\} and Malgorzata Banys and Tanja Fehm",

year = "2012",

doi = "10.1007/978-3-642-28160-0\_19",

language = "English",

isbn = "9783642281594",

series = "Recent Results in Cancer Research",

pages = "203--215",

editor = "Michail Ignatiadis and Christos Sotiriou and Klaus Pantel",

booktitle = "Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer",

}

HER2-positive DTCs/CTCs in breast cancer. / Hartkopf, Andreas D.; Banys, Malgorzata; Fehm, Tanja.
Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. ed. / Michail Ignatiadis; Christos Sotiriou; Klaus Pantel. 2012. p. 203-215 (Recent Results in Cancer Research; Vol. 195).

Research output: Chapters in Books/Reports/Conference Proceedings › Chapter › peer-review

TY - CHAP

T1 - HER2-positive DTCs/CTCs in breast cancer

AU - Hartkopf, Andreas D.

AU - Banys, Malgorzata

AU - Fehm, Tanja

PY - 2012

Y1 - 2012

N2 - The presence of circulating tumor cells (CTCs) in the blood as well as disseminated tumor cells (DTCs) in the bone marrow of breast cancer patients is associated with a worsened prognosis in the primary as well as in the metastatic situation. Next to their detection, evaluation of human epidermal growth factor receptor (HER2) expression is a valuable feature of CTCs/DTCs. As the HER2 status may change during disease progression CTCs/DTCs might (1) characterize the phenotype of minimal residual disease in the adjuvant setting and (2) serve as a "real time biopsy" of metastatic breast cancer. Phenotyping of CTCs/DTCs will thus help to understand mechanism of resistance to HER2-directed therapy. Moreover, patients that are likely to benefit from HER2-directed therapy despite a HER2-negative primary tumor might be identified.

AB - The presence of circulating tumor cells (CTCs) in the blood as well as disseminated tumor cells (DTCs) in the bone marrow of breast cancer patients is associated with a worsened prognosis in the primary as well as in the metastatic situation. Next to their detection, evaluation of human epidermal growth factor receptor (HER2) expression is a valuable feature of CTCs/DTCs. As the HER2 status may change during disease progression CTCs/DTCs might (1) characterize the phenotype of minimal residual disease in the adjuvant setting and (2) serve as a "real time biopsy" of metastatic breast cancer. Phenotyping of CTCs/DTCs will thus help to understand mechanism of resistance to HER2-directed therapy. Moreover, patients that are likely to benefit from HER2-directed therapy despite a HER2-negative primary tumor might be identified.

UR - https://www.scopus.com/pages/publications/84860585151

U2 - 10.1007/978-3-642-28160-0_19

DO - 10.1007/978-3-642-28160-0_19

M3 - Chapter

C2 - 22527508

AN - SCOPUS:84860585151

SN - 9783642281594

T3 - Recent Results in Cancer Research

SP - 203

EP - 215

BT - Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

A2 - Ignatiadis, Michail

A2 - Sotiriou, Christos

A2 - Pantel, Klaus

ER -

HER2-positive DTCs/CTCs in breast cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this